Apparent ineffectiveness of adriamycin for growth of androgen-dependent Shionogi carcinoma 115 in the mouse. 1983

Y Omukai, and S Watanabe, and T Nohno, and T Senoo, and T Saito

Although adriamycin (1 mg/kg) and 5-fluorouracil (25 mg/kg) were equally effective in inhibiting the growth of Ehrlich carcinoma, both ascites and solid forms, in the mouse, the growth of Shionogi carcinoma 115 in the male DS mouse was relatively resistant to the treatment with adriamycin as compared to 5-fluorouracil. However, direct cytotoxic activity of adriamycin in cultured Shionogi carcinoma 115 (SC 115) cells was about 1000-fold molar potent when compared with 5-fluorouracil. The apparent ineffectiveness of adriamycin against SC 115 in the DS mouse seems to be, at least in part, due to the depression of host defence mechanisms.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D002286 Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms. Ehrlich Ascites Tumor,Ascites Tumor, Ehrlich,Ehrlich Tumor Carcinoma,Tumor, Ehrlich Ascites
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

Y Omukai, and S Watanabe, and T Nohno, and T Senoo, and T Saito
December 1984, Cancer research,
Y Omukai, and S Watanabe, and T Nohno, and T Senoo, and T Saito
January 1983, Anticancer research,
Y Omukai, and S Watanabe, and T Nohno, and T Senoo, and T Saito
October 1985, Cancer research,
Y Omukai, and S Watanabe, and T Nohno, and T Senoo, and T Saito
November 1986, Cancer letters,
Y Omukai, and S Watanabe, and T Nohno, and T Senoo, and T Saito
January 1999, Nutrition and cancer,
Y Omukai, and S Watanabe, and T Nohno, and T Senoo, and T Saito
July 1992, The Journal of steroid biochemistry and molecular biology,
Y Omukai, and S Watanabe, and T Nohno, and T Senoo, and T Saito
July 1996, International journal of urology : official journal of the Japanese Urological Association,
Y Omukai, and S Watanabe, and T Nohno, and T Senoo, and T Saito
January 1987, The Prostate,
Y Omukai, and S Watanabe, and T Nohno, and T Senoo, and T Saito
December 1994, Endocrine journal,
Y Omukai, and S Watanabe, and T Nohno, and T Senoo, and T Saito
November 1990, The Journal of steroid biochemistry and molecular biology,
Copied contents to your clipboard!